Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Optimising blood-circulation and oxygen delivery in planned abdominal aortic surgery
ISRCTN ISRCTN24645910
ClinicalTrials.gov identifier
Public title Optimising blood-circulation and oxygen delivery in planned abdominal aortic surgery
Scientific title Optimising stroke volume and oxygen delivery in elective abdominal aortic surgery: a randomised controlled trial
Acronym N/A
Serial number at source N/A
Study hypothesis Elective abdominal aortic surgery is performed in patients with aneurism or occlusive atherosclerotic disease. These patients often have severe co-morbidity and are at high risk of postoperative complications. Maintaining optimal circulation during aortic surgery is difficult due to aortic cross clamping and often profound haemorrhage in combination with anaesthetising a patient with general atherosclerotic disease.

Precise and individual circulatory therapy can be performed by continuously monitoring and optimising the patient's stroke volume and oxygen delivery during and after surgery. Optimisation is performed by giving colloid boluses to achieve the individual optimal stroke volume intraoperatively, supplemented by infusion of Dobutamine postoperatively to maintain delivery of oxygen above 600 ml min-1 m-2 .

This protocol may reduce postoperative complications and death, as well as length of stay in the Intensive Care Unit and hospital.
Lay summary
Ethics approval The Local Medical Ethics Committee (Den Videnskabsetiske Komite for Region Syddanmark) approved in June 2008 (ref: S-20080055)
Study design Prospective randomised partly blinded controlled trial
Countries of recruitment Denmark
Disease/condition/study domain Elective abdominal aortic surgery; Atherosclerotic abdominal aortic occlusive disease; Abdominal aortic aneurism
Participants - inclusion criteria Consecutive patients admitted for elective abdominal aortic surgery
Participants - exclusion criteria 1. Chronic renal end-failure
2. Preoperative Lithium therapy
3. Body weight < 40 Kg (88,18 lbs)
Anticipated start date 01/06/2008
Anticipated end date 01/01/2010
Status of trial Completed
Patient information material Not available in web format, please use contact details below to request a patient information sheet
Target number of participants 85
Interventions Patients were assigned to Individual Goal Directed Therapy (IGDT) or control groups by computer-generated random sequence.

The intervention period started preoperatively, when monitoring with the Lithium Dilution Cardiac Output (LiDCO)-plus-system was established and calibrated at arrival to the operating theatre. The intervention period ended 6 hours postoperatively. Patients were followed for 30 days postoperatively.

Establishment and calibration of the LiDCO-plus-system were carried out by a member of the research team who had no involvement in the peri- and postoperative care and decision making. This allowed complete blinding of both surgical, anaesthetic and Post Anaesthetic Care Unit (PACU) clinical teams to LiDCO-plus-system readings in the control group.

All anaesthetic interventions were at the discretion of the anaesthetist responsible for the perioperative management of the patient. All patients received general anaesthesia with fentanyl, thiopental, rocuronium and sevoflurane in oxygen/air. Before induction of anaesthesia an epidural catheter was inserted at the low thoracic level and an epidural infusion of bupivacain with fentanyl was started and continued until postoperative day 2 or 3.

Standard monitoring for both groups included continuous pulse oxymetri, electrocardiography, invasive arterial and central venous blood pressure monitoring, and spirometry with inspiratory and expiratory oxygen, carbondioxide and anaesthetic gas monitoring. Arterial blood gases were analysed at predefined points in both groups.

Stroke volume index (SVI), cardiac index (CI) and oxygen delivery index (DO2I) were continuously monitored, by lithium indicator dilution and pulse power analysis using the LiDCO-plus-system in all patients, but data was blinded in the control group.

All patients were treated to achieve a heart rate < 100 bpm or <20% above baseline, a mean arterial pressure (MAP) between 60-100 mgHg, a central venous pressure (CVP) between 4-16, body temperature > 36,5°C, an arterial oxygen saturation (SaO2) > 94%, a haemoglobin concentration > 6 mmol l-1, and an urine output > 0.5-1.0 ml min-1 kg-1 in the postoperative period.

In all patients crystalloid, colloid, blood products and vasopressors were administered in the peri-and postoperative periods by the anaesthetist based on intra- and postoperative losses, standard haemodynamic parameters and blood-gases.

Intervention: Patients in the IGDT group in the peri- and postoperative period received 250 ml boluses of intravenous colloid solution (Voluven®, Fresenius Kabi AB, Upsala, Sweden ) to achieve a sustained rise in SVI of at least 10% for 20 min. Fluid boluses of Voluven® were repeated if SV subsequently decreased or if there was clinical suspicion of hypovolaemia. Furthermore, in the postoperative period, the IGDT group received dobutamine up to a maximum of 10 ug kg-1 min-1 if DO2I did not reach 600 ml min-1 m-2 with intravenous fluid alone. During infusion of dobutamine, monitoring was supplemented with 5-lead-electrocardiography, and at signs of myocardiel ischemia or heart rate > 100 min-1 or > 20% above baseline, infusion was reduced or discontinued.
Primary outcome measure(s) One or more severe postoperative complications:
1. Septic shock
2. Pneumonia
3. Superficial wound infection
4. Deep wound infection
5. Abdominal infection
6. Urinary tract infection
7. Pulmonary embolus
8. Acute Respiratory Distress Syndrome (ARDS)
9. Cardiac arrest
10. Acute coronary syndrome
11. Cardiac arrhythmia (acute treatment needed)
12. Pulmonary oedema
13. Deep venous thrombosis
14. Cerebral thrombosis
15. Cerebral haemorrhage
16. Lower limb paresis
17. Acute kidney insufficiency
18. Intraabdominal hypertension
19. Severe upper gastrointestinal bleeding
20. Gastrointestinal paralysis
21. Creatine Kinase (CK) > 5000
22. Reoperation
23. Readmission to ICU
24. Need of respirator
25. Need of hemodialysis
26. Dead
Secondary outcome measure(s) 1. Flow-related haemodynamic parameters (SVI and Do2I) measured by the LiDCO-plus-system (LiDCO Ltd., Cambridge, UK)
2. Length of stay in Intensive Care Unit
3. Length of hospital stay
Sources of funding 1. Lillebaelt Hospital Kolding (Denmark) - Local research fund
2. The Toyota Fund (Denmark)
3. Research Initiative of The Danish Society of Anaesthesiology and Intensive Care Medicine (Denmark)
Trial website
Publications 1. 2009 Conference Proceedings in
Optimizing stroke volume and oxygen delivery in elective abdominal aortic surgery – a pilot study. Bisgaard J, Rønholm E, Gilsaa T, Toft P. Acta Anaesthesiologica Scandinavica 2009, Volume 53, Issue s119 (p 68)
2. 2010 Conference Proceedings in
Optimizing stroke volume and oxygen delivery in elective abdominal aortic surgery. Bisgaard J, Rønholm E, Gilsaa T, Toft P. Critical Care 2010, 14(Suppl 1):P120 (1 March 2010) (http://ccforum.com/content/14/S1/P120)
Contact name Prof  Palle  Toft
  Address Department of Anaesthesiology and Intensive Care
Odense University Hospital
Sdr. Boulevard 29
  City/town Odense
  Zip/Postcode 5000
  Country Denmark
  Email palle.toft@ouh.regionsyddanmark.dk
Sponsor Department of Anaesthesiology Kolding (Denmark)
  Address Lillebaelt Hospital Kolding
Skovvangen 2-8
  City/town Kolding
  Zip/Postcode 6000
  Country Denmark
  Tel +45 7636 2000
  Email jannie.bisgaard@slb.regionsyddanmark.dk
Date applied 03/08/2010
Last edited 07/09/2010
Date ISRCTN assigned 03/09/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central